<p>在最近的财报电话会议上，NeuroPace, Inc. 展示了强劲的财务表现，收入增长显著，调整后的 EBITDA 也表现积极。尽管面临一些挑战，例如 DIXI 产品线的逐步结束和儿童适应症的时间延长，但整体情绪乐观，得益于战略进展和积极的发展。</p>
<h2>创纪录的收入和增长</h2>
<p>NeuroPace 报告称，2025 年第三季度的总收入创下 2740 万美元的纪录，同比增长 30%，而去年同期为 2110 万美元。这一令人印象深刻的增长主要得益于 RNS 初始植入，RNS 收入达到 2260 万美元，比去年增长 31%。</p>
<h2>积极的调整后 EBITDA</h2>
<p>NeuroPace 首次实现了正的调整后 EBITDA，突显了公司强大的可扩展性和严格的费用管理。这一里程碑反映了公司在扩大市场份额的同时高效管理运营的能力。</p>
<h2>增加的收入和毛利率指引</h2>
<p>NeuroPace 将全年的收入指引上调至 9700 万至 9800 万美元，较之前的 9400 万至 9800 万美元有所提高。这一调整反映了预计 21% 至 23% 的同比增长。此外，毛利率指引也上调至 76% 至 77%，高于之前的 75% 至 76%。</p>
<h2>FDA 提交进展</h2>
<p>关于 NAUTILUS 研究和儿童适应症的进展报告，预计 NAUTILUS 的 PMA 补充申请将在年底前提交。这一进展强调了 NeuroPace 扩大产品供应和开拓新市场领域的承诺。</p>
<h2>强劲的 RNS 系统表现</h2>
<p>RNS 系统继续表现强劲，毛利率保持在 80% 以上。这一表现得益于制造效率的提高和有利的定价，促进了公司的整体财务成功。</p>
<h2>同行认可</h2>
<p>RNS 系统因其独特的闭环刺激能力在《临床神经生理学杂志》上获得认可，进一步巩固了 NeuroPace 在神经刺激技术领域的领导地位。</p>
<h2>DIXI 产品线的逐步结束</h2>
<p>公司宣布结束 DIXI 产品线，该季度销售额约为 400 万美元。分销协议于 9 月 30 日正式结束，逐步结束期将持续到 2026 年第一季度末。</p>
<h2>儿童适应症的时间延长</h2>
<p>儿童适应症提交的时间表已延长至 2025 年之后，原因是需要时间来协调协议和数据集。这一延长反映了公司确保提交全面和准确的承诺。</p>
<h2>净亏损</h2>
<p>NeuroPace 报告称，该季度净亏损为 350 万美元，较去年同期的 550 万美元净亏损有所改善。这一净亏损的减少表明公司在实现财务稳定方面取得了进展。</p>
<h2>前瞻性指引</h2>
<p>展望未来，NeuroPace 提供了更新的财务指引，预计季度收入创纪录，同比增长 30%，主要得益于 RNS 初始植入。公司预计全年的收入将在 9700 万至 9800 万美元之间，毛利率预计将在 76% 至 77% 之间。NeuroPace 致力于维持长期增长轨迹，目标是在其核心 RNS 业务中实现至少 20% 的增长。</p>
<p>总之，NeuroPace 的财报电话会议描绘了公司财务健康和战略方向的积极前景。凭借创纪录的收入增长、积极的调整后 EBITDA 和增加的指引，公司在持续成功的道路上处于良好位置。尽管面临一些挑战，NeuroPace 的强劲表现和前瞻性战略为投资者和利益相关者提供了良好的前景。</p>

NPCE

<p>NeuroPace, Inc. 报告称 2025 年第三季度创下 2740 万美元的收入，较去年同期增长 30%，主要得益于 RNS 初始植入。该公司首次实现正向调整后息税折旧摊销前利润（EBITDA），反映出强劲的可扩展性。全年收入指引上调至 9700 万至 9800 万美元，预计毛利率为 76% 至 77%。尽管净亏损为 350 万美元，较去年有所改善，NeuroPace 对未来增长仍持乐观态度，目标是在其核心 RNS 业务中实现至少 20% 的增长。该公司致力于扩展产品线并开拓新的市场领域</p>

<p>In a recent earnings call, NeuroPace, Inc. showcased a robust financial performance with strong revenue growth and positive adjusted EBITDA. Despite some challenges, such as the winding down of the DIXI product line and extended timelines for pediatric indication, the overall sentiment was optimistic, driven by strategic progress and positive developments.</p>
<div class="lb-trans"><p>在最近的财报电话会议上，NeuroPace, Inc. 展示了强劲的财务表现，收入增长显著，调整后的 EBITDA 也表现积极。尽管面临一些挑战，例如 DIXI 产品线的逐步结束和儿童适应症的时间延长，但整体情绪乐观，得益于战略进展和积极的发展。</p>
</div><h2>Record Revenue and Growth</h2>
<div class="lb-trans"><h2>创纪录的收入和增长</h2>
</div><p>NeuroPace reported a record total revenue of $27.4 million for Q3 2025, representing a significant 30% year-over-year growth compared to $21.1 million in the previous year. This impressive increase was primarily fueled by the RNS initial implants, with RNS revenue reaching $22.6 million, marking a 31% growth from the prior year.</p>
<div class="lb-trans"><p>NeuroPace 报告称，2025 年第三季度的总收入创下 2740 万美元的纪录，同比增长 30%，而去年同期为 2110 万美元。这一令人印象深刻的增长主要得益于 RNS 初始植入，RNS 收入达到 2260 万美元，比去年增长 31%。</p>
</div><h2>Positive Adjusted EBITDA</h2>
<div class="lb-trans"><h2>积极的调整后 EBITDA</h2>
</div><p>For the first time in its history, NeuroPace achieved a positive adjusted EBITDA, highlighting the company’s strong scalability and disciplined expense management. This milestone reflects the company’s ability to efficiently manage its operations while expanding its market presence.</p>
<div class="lb-trans"><p>NeuroPace 首次实现了正的调整后 EBITDA，突显了公司强大的可扩展性和严格的费用管理。这一里程碑反映了公司在扩大市场份额的同时高效管理运营的能力。</p>
</div><h2>Increased Revenue and Gross Margin Guidance</h2>
<div class="lb-trans"><h2>增加的收入和毛利率指引</h2>
</div><p>NeuroPace raised its full-year revenue guidance to a range of $97 million to $98 million, up from the previous guidance of $94 million to $98 million. This adjustment reflects an anticipated 21% to 23% year-over-year growth. Additionally, the gross margin guidance was increased to 76% to 77%, up from 75% to 76%.</p>
<div class="lb-trans"><p>NeuroPace 将全年的收入指引上调至 9700 万至 9800 万美元，较之前的 9400 万至 9800 万美元有所提高。这一调整反映了预计 21% 至 23% 的同比增长。此外，毛利率指引也上调至 76% 至 77%，高于之前的 75% 至 76%。</p>
</div><h2>FDA Submission Progress</h2>
<div class="lb-trans"><h2>FDA 提交进展</h2>
</div><p>Progress was reported on the NAUTILUS study and the pediatric indication, with the PMA supplement for NAUTILUS expected to be submitted by the end of the year. This advancement underscores NeuroPace’s commitment to expanding its product offerings and addressing new market segments.</p>
<div class="lb-trans"><p>关于 NAUTILUS 研究和儿童适应症的进展报告，预计 NAUTILUS 的 PMA 补充申请将在年底前提交。这一进展强调了 NeuroPace 扩大产品供应和开拓新市场领域的承诺。</p>
</div><h2>Strong RNS System Performance</h2>
<div class="lb-trans"><h2>强劲的 RNS 系统表现</h2>
</div><p>The RNS System continued to perform strongly, with a gross margin remaining above 80%. This performance was supported by improved manufacturing efficiency and favorable pricing, contributing to the company’s overall financial success.</p>
<div class="lb-trans"><p>RNS 系统继续表现强劲，毛利率保持在 80% 以上。这一表现得益于制造效率的提高和有利的定价，促进了公司的整体财务成功。</p>
</div><h2>Peer Recognition</h2>
<div class="lb-trans"><h2>同行认可</h2>
</div><p>The RNS System received recognition in the Journal of Clinical Neurophysiology for its unique closed-loop stimulation capabilities, further establishing NeuroPace’s reputation as a leader in neurostimulation technology.</p>
<div class="lb-trans"><p>RNS 系统因其独特的闭环刺激能力在《临床神经生理学杂志》上获得认可，进一步巩固了 NeuroPace 在神经刺激技术领域的领导地位。</p>
</div><h2>DIXI Product Line Wind Down</h2>
<div class="lb-trans"><h2>DIXI 产品线的逐步结束</h2>
</div><p>The company announced the conclusion of its DIXI product line, with sales amounting to approximately $4 million in the quarter. The distribution agreement officially ended on September 30, and the wind-down period will continue until the end of Q1 2026.</p>
<div class="lb-trans"><p>公司宣布结束 DIXI 产品线，该季度销售额约为 400 万美元。分销协议于 9 月 30 日正式结束，逐步结束期将持续到 2026 年第一季度末。</p>
</div><h2>Extended Timeline for Pediatric Indication</h2>
<div class="lb-trans"><h2>儿童适应症的时间延长</h2>
</div><p>The timeline for the pediatric indication submission has been extended beyond 2025 due to the time required to align the protocol and data set. This extension reflects the company’s commitment to ensuring comprehensive and accurate submissions.</p>
<div class="lb-trans"><p>儿童适应症提交的时间表已延长至 2025 年之后，原因是需要时间来协调协议和数据集。这一延长反映了公司确保提交全面和准确的承诺。</p>
</div><h2>Net Loss</h2>
<div class="lb-trans"><h2>净亏损</h2>
</div><p>NeuroPace reported a net loss of $3.5 million for the quarter, an improvement from the $5.5 million net loss in the same period last year. This reduction in net loss indicates progress towards financial stability.</p>
<div class="lb-trans"><p>NeuroPace 报告称，该季度净亏损为 350 万美元，较去年同期的 550 万美元净亏损有所改善。这一净亏损的减少表明公司在实现财务稳定方面取得了进展。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指引</h2>
</div><p>Looking ahead, NeuroPace has provided updated financial guidance, projecting record quarterly revenue and a 30% year-over-year growth driven by RNS initial implants. The company expects full-year revenue to be between $97 million and $98 million, with gross margins anticipated to be between 76% and 77%. NeuroPace is committed to sustaining a long-term growth trajectory, targeting a minimum of 20% growth in its core RNS business.</p>
<div class="lb-trans"><p>展望未来，NeuroPace 提供了更新的财务指引，预计季度收入创纪录，同比增长 30%，主要得益于 RNS 初始植入。公司预计全年的收入将在 9700 万至 9800 万美元之间，毛利率预计将在 76% 至 77% 之间。NeuroPace 致力于维持长期增长轨迹，目标是在其核心 RNS 业务中实现至少 20% 的增长。</p>
</div><p>In summary, NeuroPace’s earnings call painted a positive picture of the company’s financial health and strategic direction. With record revenue growth, positive adjusted EBITDA, and increased guidance, the company is well-positioned for continued success. Despite some challenges, NeuroPace’s strong performance and forward-looking strategies offer promising prospects for investors and stakeholders.</p>
<div class="lb-trans"><p>总之，NeuroPace 的财报电话会议描绘了公司财务健康和战略方向的积极前景。凭借创纪录的收入增长、积极的调整后 EBITDA 和增加的指引，公司在持续成功的道路上处于良好位置。尽管面临一些挑战，NeuroPace 的强劲表现和前瞻性战略为投资者和利益相关者提供了良好的前景。</p>
</div>

NeuroPace, Inc. 报告创下纪录的收入和增长